Section Arrow
MRNA.NASDAQ
- Moderna
Quotes are at least 15-min delayed:2026/11/10 12:33 EST
Regular Hours
Last
 256.01
-12.99 (-4.83%)
Day High 
272.9999 
Prev. Close
269 
1-M High
280.8 
Volume 
5.63M 
Bid
255.71
Ask
256.26
Day Low
252.07 
Open
265.885 
1-M Low
179.53 
Market Cap 
107.39B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 233.89 
20-SMA 227.62 
50-SMA 194.47 
52-W High 280.8 
52-W Low 22.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.98/-4.05
Enterprise Value
108.66B
Balance Sheet
Book Value Per Share
17.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.92B
Operating Revenue Per Share
22.77
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PEPGPepGen5.27+2.88+120.50%-- 
HUMAHumacyte0.56995+0.11475+25.21%-- 
ZURAZura Bio Limited1.465+0.225+18.15%-- 
CTMXCytomX Therapeutics1.965-0.015-0.76%-- 
IBRXImmunityBio6.91-0.2-2.81%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.